Inactive Instrument

Highlights Oncomed Pharmaceuticals Inc

Equities

US68234X1028

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Celgene Corporation Announces Update on Etigilimab Partnership	19-06-13	CI
OncoMed Pharmaceuticals, Inc. Announces Executive Resignations in Connection with the Merger Agreement	19-04-23	CI
Mereo BioPharma Group plc completed the acquisition of OncoMed Pharmaceuticals, Inc. from Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., MSI BVF SPV, LLC and Biotechnology Value Trading Fund OS LP managed by BVF Partners LP and others.	19-04-22	CI
OncoMed Pharmaceuticals, Inc. Declares Special Dividend of Contingent Value Rights, Payable on April 5, 2019	19-03-15	CI
OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2018	19-03-07	CI
Mereo BioPharma Group plc agreed to acquire OncoMed Pharmaceuticals, Inc. for $57.4 million.	18-12-04	CI
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody	18-11-09	CI
Oncomed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2018	18-11-01	CI
Celgene Notifies OncoMed Pharmaceuticals, Inc. of Its Decision Not to Exercise Option to License Rosmantuzumab and Subsequently Terminated the Companies’ Collaboration Agreement with Respect to Rosmantuzumab, Effective February 12, 2019	18-10-17	CI
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting	18-10-09	CI
OncoMed Pharmaceuticals, Inc. Announces Publication of Phase 1a Data of Navicixizumab	18-09-24	CI
OncoMed Pharmaceuticals, Inc. Provides Update on Navicixizumab Partnership	18-09-20	CI
Oncomed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-02	CI
Oncomed Pharmaceuticals Inc. Doses First Patient in Phase 1b Portion of Anti-TIGIT Clinical Trial	18-06-12	CI
OncoMed Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018; Provides Earnings Guidance for the Year 2018	18-05-08	CI
OncoMed Pharmaceuticals Inc. Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting	18-04-18	CI
Oncomed Pharmaceuticals, Inc. Reports Unaudited Earning Results for the Quarter and Year Ended December 31, 2017	18-03-08	CI
OncoMed Pharmaceuticals, Inc. Announces an Update on the Rosmantuzumab Clinical Program	18-01-04	CI
Oncomed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Provides Cash Flow Guidance for the Year 2017	17-11-02	CI
OncoMed Pharmaceuticals, Inc. Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial	17-09-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oncomed Pharmaceuticals Inc

Equities

US68234X1028

Highlights

Filters